A
Alcista
Alcista · 25%BNTX
$156.60
Precio del escenario
$89.670
-1.587 (-1.77%)Al cierre
Loading chart…
- Máximo
- 92.730
- Apertura
- 90.750
- Precio medio ponderado por volumen
- 90.48
- Volumen
- 1.16M
- Capitalización
- 19.37B
- Mínimo
- 89.030
- Importe
- 105.36M
- EV/EBITDA, TTM
- -0.98
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Análisis de IA of Biontech SE (BNTX)
MantenerGiven the current price of $87.71 and a forward P/E of 7.04, BioNTech may appear undervalued, but the recent negative trial results and a 9.54% drop over the past five days suggest caution. The stock's RSI of 28.47 indicates it is oversold, yet the ongoing leadership changes and disappointing trial outcomes pose risks. Therefore, it is advisable to hold rather than buy at this time.
Métricas de valoración
El PER previsto actual de Biontech SE (BNTX) es 7.04, frente a su media de 5 años de -3.69.
Escenarios de precio de Alphio AI para BNTX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BNTX en cartera
Cronología de eventos
Noticias
9.510-18FoolBioNTech Faces Setbacks in Clinical Trials Amid Pipeline Hopes
7.510-17FoolBioNTech's Cash Reserves and Promising Cancer Pipeline Signal Growth Potential
7.010-14PRnewswireBioNTech's AHEAD-MERIT Trial Misses Key Endpoint, Investors Face Losses
2.010-14stocktwitsBioNTech's mRNA Cancer Therapy Faces Setbacks
9.010-13stocktwitsBioNTech's Cancer Trial Results Disappoint
Preguntas frecuentes sobre BNTX, respondidas por Alphio AI
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders. It operates in the Healthcare sector.
Given the current price of $87.71 and a forward P/E of 7.04, BioNTech may appear undervalued, but the recent negative trial results and a 9.54% drop over the past five days suggest caution. The stock's RSI of 28.47 indicates it is oversold, yet the ongoing leadership changes and disappointing trial outcomes pose risks. Therefore, it is advisable to hold rather than buy at this time.
Comunidad
Más ↗
$BNTX (+6.2% pre) BioNTech drug shows doubled survival in lung cancer trial
Mostrar más
BioNTech was downgraded by analysts at BMO Capital, and here is the reasoning behind the move - $BNTX
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.